TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36351726

Group type: EXPERIMENTAL
Intervention: e‐WOMAC
Number of subjects: 70

Group type: COMPARATOR
Intervention: p‐WOMAC
Number of subjects: 70
Study: 34698397

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BUP-NX)
Number of subjects: 474
Study: 32017703

Group type: EXPERIMENTAL
Intervention: Educational intervention delivered to senior nursing students
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 90
Study: 36451459

Group type: EXPERIMENTAL
Intervention: PN + EN (supplemental parenteral nutrition)
Number of subjects: 72

Group type: COMPARATOR
Intervention: TEN (total enteral nutrition)
Number of subjects: 72
Study: 34598737

Group type: EXPERIMENTAL
Intervention: Family-group cognitive-behavioral (FGCB) preventive intervention (12 sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intervention (usual care)
Number of subjects: 100
Study: 35690515

Group type: EXPERIMENTAL
Intervention: 18F-PSMA-11 PET/CT
Number of subjects: 82

Group type: COMPARATOR
Intervention: 68Ga-PSMA-11 PET/CT
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 18F-PSMA-11
Number of subjects: 82

Group type: COMPARATOR
Intervention: 68Ga-PSMA-11
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 18F-PSMA-11 and 68Ga-PSMA-11
Number of subjects: 82
Study: 34261523

Group type: EXPERIMENTAL
Intervention: Passive remote monitoring technology
Number of subjects: 29

Group type: COMPARATOR
Intervention: Home care services
Number of subjects: 29

Group type: COMPARATOR
Intervention: Family/friend caregiver support
Number of subjects: 29

Group type: COMPARATOR
Intervention: Residential long-term care homes
Number of subjects: 29
Study: 32527290

Group type: EXPERIMENTAL
Intervention: Less invasive surfactant administration (LISA)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Endotracheal surfactant administration followed by low peak pressure ventilation (LPPSA)
Number of subjects: 600
Study: 34986284

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy plus eltrombopag (Group B)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Immunosuppressive therapy (Group A)
Number of subjects: 197
Study: 34554372

Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg o.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Letrozole (2.5 mg o.d.)
Number of subjects: 0
Study: 32462216

Group type: EXPERIMENTAL
Intervention: Physical examination for surgical disease
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Surgical needs survey administered by surgeons
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Assessment of surgical histories
Number of subjects: 780
Study: 33942548

Group type: EXPERIMENTAL
Intervention: Robotic guidance group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Freehand group
Number of subjects: 30
Study: 32046671

Group type: COMPARATOR
Intervention: Motor-based treatment consistent with current best practices in speech therapy (40% of participants)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Treatment incorporating visual biofeedback (60% of participants)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Real-time visual display of the acoustic signal of speech (within biofeedback condition)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ultrasound imaging of the tongue during speech (within biofeedback condition)
Number of subjects: 110
Study: 33021580

Group type: EXPERIMENTAL
Intervention: Leg extension (LE) power
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Knee extension (KE) torque
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Leg press one repetition maximum (LP RM)
Number of subjects: 80
Study: 33345312

Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (CMX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Free gingival graft (FGG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Histological assessment
Number of subjects: 30
Study: 36174151

Group type: EXPERIMENTAL
Intervention: trauma‐focused expressive writing (EW)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: neutral expressive writing (EW)
Number of subjects: 28

Group type: COMPARATOR
Intervention: control
Number of subjects: 28
Study: 33602279

Group type: EXPERIMENTAL
Intervention: Nicotine supplementation (2 mg)
Number of subjects: 11
Study: 32727558

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU oral drop daily for 5 days)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (1000 IU daily for 5 days)
Number of subjects: 74
Study: 35306032

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 40
Study: 34702730

Group type: EXPERIMENTAL
Intervention: 16-week cognitive rehabilitation programme
Number of subjects: 75
Study: 35390457

Group type: EXPERIMENTAL
Intervention: Topical Cannabidiol (CBD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Essential Oil (EO)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Topical Cannabidiol (CBD) + Essential Oil (EO)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 80
Study: 35927059

Group type: EXPERIMENTAL
Intervention: Serratus plane block combined with pectoral nerve block I before general anesthesia + PCIA
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anesthesia alone + PCIA (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Serratus plane block combined with pectoral nerve block I + PCIA
Number of subjects: 30
Study: 36341490

Group type: EXPERIMENTAL
Intervention: Sexual advertisements
Number of subjects: 182

Group type: COMPARATOR
Intervention: Nonsexual advertisements
Number of subjects: 182
Study: 34607574

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 35762079

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 38

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 38
Study: 33833944

Group type: EXPERIMENTAL
Intervention: Myval THV
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sapien 3 THV
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sapien XT THV
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Myval THV vs Sapien XT THV
Number of subjects: 108
Study: 35488509

Group type: EXPERIMENTAL
Intervention: PSO17 10%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PSO17 20%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 12
Study: 33293201

Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT) - one guided online group session
Number of subjects: 72

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 72
Study: 35753072

Group type: EXPERIMENTAL
Intervention: Preoperative high‐intensity interval training (HIIT), four times weekly (EX; n = 20)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preoperative high‐intensity interval training (HIIT) (EX; n = 20)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (CON; n = 10)
Number of subjects: 30
Study: 34551471

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg IV)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (2 ml saline IV)
Number of subjects: 90
Study: 35366811

Group type: EXPERIMENTAL
Intervention: Left lateral position (Group L)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine position (Group S)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 33581481

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice weekly sessions
Number of subjects: 0
Study: 32556293

Group type: EXPERIMENTAL
Intervention: COVID‐19 prognostic signature based on neutrophil count, lymphocyte count, procalcitonin, age, and C‐reactive protein
Number of subjects: 0

Group type: COMPARATOR
Intervention: COVID‐19 prognostic signature
Number of subjects: 0
Study: 35428889

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 mcg daily)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg every 6 months)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sequential treatment with teriparatide followed by denosumab
Number of subjects: 41
Study: 33753685

Group type: EXPERIMENTAL
Intervention: Dangerous practices observed among barbers
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Better attitude regarding BBVI
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Increased years of schooling
Number of subjects: 138
Study: 32732022

Group type: EXPERIMENTAL
Intervention: Information leaflet
Number of subjects: 988

Group type: COMPARATOR
Intervention: Control
Number of subjects: 988
Study: 36229342

Group type: EXPERIMENTAL
Intervention: Intranasal ChAdOx1 nCoV-19 (5 × 10^9 VP, n=6)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intranasal ChAdOx1 nCoV-19 (2 × 10^10 VP, n=12)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intranasal ChAdOx1 nCoV-19 (5 × 10^10 VP, n=12)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intranasal ChAdOx1 nCoV-19 (5 × 10^10 VP) as a booster
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular mRNA SARS-CoV-2 vaccination
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intramuscular ChAdOx1 nCoV-19
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intranasal ChAdOx1 nCoV-19
Number of subjects: 30
Study: 33406103

Group type: EXPERIMENTAL
Intervention: Wilderness programs employing adventure therapy
Number of subjects: 15
Study: 34983195

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Hypertension in women
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Dyslipidemia in men
Number of subjects: 1298
Study: 33273048

Group type: EXPERIMENTAL
Intervention: UBICARE technology
Number of subjects: 0
Study: 32948350

Group type: EXPERIMENTAL
Intervention: Sugar absorption test on days 4, 7, and 14 postpartum
Number of subjects: 12
Study: 34491219

Group type: EXPERIMENTAL
Intervention: Teaching parents about dengue using a booklet
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Teaching parents about dengue without a booklet
Number of subjects: 142

Group type: COMPARATOR
Intervention: Learning from an expert
Number of subjects: 142

Group type: COMPARATOR
Intervention: Learning about an unrelated topic
Number of subjects: 142
Study: 32440004

Group type: EXPERIMENTAL
Intervention: PAP (post-activation potentiation) warm-up consisting of 2×5 arm-pulls with resistance bands
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-PAP (control condition) warm-up
Number of subjects: 12
Study: 35013427

Group type: EXPERIMENTAL
Intervention: Post-treatment control (individuals who can stop ART without viral load rebound)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Risk Score based on expression of four genes (ISG15, XAF1, TRIM25, USP18)
Number of subjects: 14
Study: 33725860

Group type: EXPERIMENTAL
Intervention: Arthroscopic repair of bursal‐sided partial-thickness rotator cuff tears
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arthroscopic repair of articular‐sided partial-thickness rotator cuff tears
Number of subjects: 0
Study: 32631243

Group type: EXPERIMENTAL
Intervention: Work Stress Questionnaire (WSQ) intervention with physicians' feedback
Number of subjects: 271

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 271
Study: 35487712

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 0
Study: 33847426

Group type: EXPERIMENTAL
Intervention: Seeking Safety/Signs of Safety model
Number of subjects: 500000
Study: 34506719

Group type: EXPERIMENTAL
Intervention: Laughter therapy (LT) twice a week for 2 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Waiting-list control (no treatment during the same period)
Number of subjects: 41
Study: 32083766

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (50.4 Gy in supraclavicular field and 56 Gy in mediastinal field in 28 fractions over 6 weeks)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 157
Study: 35098613

Group type: EXPERIMENTAL
Intervention: Active rTMS (0.25 Hz, 60 stimuli each, 2 sessions)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham rTMS (0.25 Hz, 60 stimuli each, 2 sessions)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 62
Study: 33691760

Group type: EXPERIMENTAL
Intervention: Decision aid ('Kidney Stone Choice')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 35437092

Group type: EXPERIMENTAL
Intervention: JumpMath
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cogmed
Number of subjects: 29

Group type: COMPARATOR
Intervention: Active Control/Reading
Number of subjects: 29
Study: 33950375

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1452
Study: 33177734

Group type: EXPERIMENTAL
Intervention: Self-management exercise intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional intervention
Number of subjects: 70
Study: 35843545

Group type: EXPERIMENTAL
Intervention: Bipolar salpingectomy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Traditional salpingectomy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 51
Study: 33547015

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) after RYGB
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ethinylestradiol (EE) after RYGB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Levonorgestrel (LNG) in controls
Number of subjects: 20
Study: 33547855

Group type: EXPERIMENTAL
Intervention: Allogeneic acellular dermal matrix (ADM) combined with autologous razor-thin graft
Number of subjects: 64

Group type: COMPARATOR
Intervention: Autologous scar tissue combined with autologous razor-thin graft
Number of subjects: 64
Study: 35869334

Group type: EXPERIMENTAL
Intervention: 3D display technique
Number of subjects: 89

Group type: COMPARATOR
Intervention: 4K-2D display technique
Number of subjects: 89
Study: 33211870

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg SC Q6M (long-term arm)
Number of subjects: 1969

Group type: COMPARATOR
Intervention: Placebo (crossover arm)
Number of subjects: 1969
Study: 35908037

Group type: EXPERIMENTAL
Intervention: Preoperative strengthening exercise program
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 129
Study: 33065774

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (SOF/VEL) plus ribavirin for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (no DAA therapy)
Number of subjects: 0
Study: 33865519

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (ARNI)
Number of subjects: 256
Study: 35575618

Group type: EXPERIMENTAL
Intervention: Choline supplementation (550 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (25 mg/d d9-choline)
Number of subjects: 30
Study: 33665769

Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF) at day 3
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF) at day 5
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF) at hospital discharge
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor (VEGF) at day 1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor (VEGF) at hospital discharge
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Repeated measures of BDNF
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Repeated measures of VEGF
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Neuron specific enolase (NSE) at day 0
Number of subjects: 44
Study: 32772684

Group type: EXPERIMENTAL
Intervention: DTAS
Number of subjects: 60

Group type: COMPARATOR
Intervention: CTT
Number of subjects: 60
Study: 35778856

Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Protease inhibitor
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Stavudine
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Hepatitis C
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Higher baseline CD4 count
Number of subjects: 2614
Study: 33409691

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 70S30C‐BAG
Number of subjects: 70
Study: 32484629

Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion
Number of subjects: 418

Group type: COMPARATOR
Intervention: vehicle lotion
Number of subjects: 418
Study: 33890535

Group type: EXPERIMENTAL
Intervention: Bangerter filters (BF) strength 0.1
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bangerter filters (BF) strength 0.2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bangerter filters (BF) strength 0.4
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bangerter filters (BF) strength 0.6
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bangerter filters (BF) (all strengths)
Number of subjects: 23
Study: 32519957

Group type: EXPERIMENTAL
Intervention: 3% polidocanol
Number of subjects: 150

Group type: COMPARATOR
Intervention: 5% phenol
Number of subjects: 150
Study: 35346103

Group type: EXPERIMENTAL
Intervention: Minimally invasive radical hysterectomy using an endoscopic stapler
Number of subjects: 124

Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy
Number of subjects: 124
Study: 32959909

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32990609

Group type: EXPERIMENTAL
Intervention: Eel biscuits
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard hospital snacks
Number of subjects: 40
Study: 32869680

Group type: EXPERIMENTAL
Intervention: Topical tretinoin 0.05% cream
Number of subjects: 25

Group type: COMPARATOR
Intervention: Moisturizer
Number of subjects: 25
Study: 36006951

Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery (GraMI) protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 615918191

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 35350983

Group type: EXPERIMENTAL
Intervention: ESP block with 2 mg/kg levobupivacaine
Number of subjects: 35

Group type: COMPARATOR
Intervention: ESP block with 2 mg/kg levobupivacaine and 5 μg/mL epinephrine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups (L and LE)
Number of subjects: 35
Study: 33358456

Group type: EXPERIMENTAL
Intervention: Combined nerve blocks (NER group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (CON group)
Number of subjects: 102
Study: 34736429

Group type: EXPERIMENTAL
Intervention: Tomotherapy (TT)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Conventional radiotherapy (CR)
Number of subjects: 123
Study: 33081774

Group type: EXPERIMENTAL
Intervention: Multiple-player VR (MP) group
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Single-player VR (SP) group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Textbook reading control group (CG)
Number of subjects: 18
Study: 32876710

Group type: EXPERIMENTAL
Intervention: Arthroscopic osteochondroplasty
Number of subjects: 214

Group type: COMPARATOR
Intervention: Arthroscopic lavage
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 214
Study: 35249825

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SHAM (placebo)
Number of subjects: 40
Study: 34921133

Group type: EXPERIMENTAL
Intervention: High erythropoietin (Epo) treatment in wild‐type mice and human volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EpoR signaling
Number of subjects: 0
Study: 36093566

Group type: EXPERIMENTAL
Intervention: 100 μg selenium as selenium-enriched yeast
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: 200 μg selenium as selenium-enriched yeast
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: 300 μg selenium as selenium-enriched yeast
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: 100, 200, or 300 μg selenium as selenium-enriched yeast
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo-yeast
Number of subjects: 481
Study: 32374188

Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced high-protein diet (CRHP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional diabetes diet (CD)
Number of subjects: 30
Study: 35280833

Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg daily for 5 days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 66
Study: 33070129

Group type: EXPERIMENTAL
Intervention: High-variability practice (multiple words)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-variability practice (single word)
Number of subjects: 8
Study: 34230624

Group type: EXPERIMENTAL
Intervention: Newly developed predictive equation for FFM: FFM = 16.284 + 0.442 × (Height2/Resistance) − 0.13 × age + 0.302 × Weight − 0.121 × Waist Circumference; r2 = 0.86; SEE = 2.32 kg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Newly developed predictive equation for LSTM: LSTM = 14.732 + 0.427 × (Height2/Resistance) − 0.125 × age + 0.291 × Weight − 0.115 × Waist Circumference; r2 = 0.92; SEE = 2.29 kg
Number of subjects: 222